PharmaNet hires vp for clinical operations

Catherine Derasp will oversee Phase I clinics

Catherine Derasp has joined PharmaNet Development Group, a US provider of clinical development services to the pharmaceutical and biotechnology industry, as vice president, clinical operations of the company's Phase I clinics.

Derasp will oversee the management of the company's 350-bed Phase I clinical operations that are located in Montreal and Quebec City, Canada. In addition to first-in-man and proof-of-concept phase I clinical services, she will be responsible for a variety of studies in special populations, cardiac safety testing, and drug-drug interaction studies.

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Regulatory

AMR Bio urges US policymakers to make infection prevention a core AMR strategy

Submitted ahead of PACCARB's 27th public meeting, AMR Bio's recommendations call for topical antimicrobials such as MRSA-active XF-73 to receive federal support alongside conventional antibiotic development
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NICE approval is not enough: why the UK’s next medicines challenge is operational delivery

A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR
Regulatory

What to expect from a regulatory inspection: An NSF expert guide

Prepare with confidence. NSF’s expert guide shows what inspectors look for, common pitfalls and how to ensure lasting inspection readiness
Subscribe now